AURORA(SH:600666)2014-03-14 16:00Financial Performance - The company's total revenue for 2013 was CNY 1,326,950,812.70, representing a 4.42% increase compared to CNY 1,270,797,952.05 in 2012[19] - The net profit attributable to shareholders for 2013 was CNY 32,745,802.60, a decrease of 19.67% from CNY 40,763,458.81 in 2012[19] - The net profit after deducting non-recurring gains and losses was CNY 20,532,622.61, down 48.10% from CNY 39,565,665.45 in 2012[19] - The total operating revenue for 2013 was CNY 1,326,950,812.70, an increase of 4.9% compared to CNY 1,270,797,952.05 in the previous year[121] - The net profit for the year was CNY 32,010,766.88, a decrease of 22.8% from CNY 41,476,791.41 in the previous year[121] Cash Flow - The net cash flow from operating activities was negative CNY 41,221,439.01, a decline of 157.78% compared to CNY 71,337,979.59 in 2012[19] - The company's cash flow from operating activities showed a significant decline, with a net outflow of CNY 41,221,439.01 compared to a net inflow of CNY 71,337,979.59 in the previous year[28] - Cash inflows from operating activities totaled CNY 2.44 billion, a decrease of 12.0% from CNY 2.77 billion in the previous period[125] - The net cash flow from operating activities is negative CNY 41.22 million, compared to a positive CNY 71.34 million in the previous period[126] Assets and Liabilities - The total assets at the end of 2013 were CNY 1,981,692,427.44, an increase of 22.05% from CNY 1,623,718,854.18 in 2012[19] - The total liabilities increased to CNY 1,431,902,616.37 from CNY 1,115,545,278.59, representing a rise of 28.3%[119] - The company's cash and cash equivalents at the end of the period totaled RMB 340,838,467.18, an increase from RMB 300,644,634.66 at the beginning of the period[191] - The accounts receivable at the end of the period amounted to RMB 282,527,969.70, with a provision for bad debts of RMB 29,657,604.63[196] Shareholder Information - The company plans to distribute a cash dividend of CNY 0.14 per 10 shares, totaling CNY 4.062 million, based on the share capital as of December 31, 2013[4] - The company distributed a cash dividend of RMB 0.11 per share to shareholders, totaling RMB 3.1916 million, based on the 2012 fiscal year[50] - The total number of shares is 290,146,298, with 100% being tradable shares[65] - The largest shareholder, Chongqing Taiji Industrial (Group) Co., Ltd., holds 32.39% of the shares, totaling 93,980,381 shares[67] Investments and Acquisitions - The company completed the acquisition of a 74.65% stake in Taiji Pharmaceutical, becoming its controlling shareholder[26] - The company acquired a 74.65% stake in Taiji Group Sichuan Taiji Pharmaceutical Co., Ltd. for RMB 37.41 million, effective from July 2013[187] - The company has paid a total of RMB 30 million for the technology transfer of the recombinant human interferon ω injection, with the project still in the clinical research phase as of December 31, 2013[44] Research and Development - The company’s R&D expenditure was CNY 12,139,615.19, showing a slight increase of 0.04% from the previous year[28] - Research and development expenses amounted to ¥12,139,615.19, representing 2.84% of net assets and 0.91% of operating income[31] Market and Industry Outlook - The Chinese pharmaceutical market is projected to grow at approximately 20% annually, potentially surpassing the US and Japan by 2020, becoming the largest pharmaceutical market globally[46] - The national healthcare reform has seen an investment exceeding RMB 1.5 trillion from 2009 to 2013, which is expected to accelerate market expansion in the pharmaceutical sector[45] Governance and Compliance - The company has maintained a strict governance structure, ensuring compliance with laws and regulations, and protecting the interests of all shareholders[90] - The audit committee provided a standard unqualified opinion on the company's 2013 annual financial report, confirming its compliance with accounting standards[99] - The company has not received any penalties or public reprimands from the China Securities Regulatory Commission during the year[61] Employee Information - The total number of employees in the parent company is 1,790, and the total number of employees in major subsidiaries is 372, resulting in a combined total of 2,162 employees[84] - The professional composition includes 1,400 production personnel, 173 sales personnel, 178 technical personnel, 40 financial personnel, and 371 administrative personnel[84] Financial Reporting and Accounting Policies - The financial statements comply with the requirements of enterprise accounting standards, reflecting the company's financial status accurately[144] - The company has not made any changes to accounting policies or estimates in the reporting period[181] - The company recognizes revenue from the sale of goods when the risks and rewards of ownership have transferred to the buyer, and the amount of revenue can be reliably measured[176]